Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.

Christi M J Steendam,Sophie M Ernst,Sushil K Badrising,Marthe S Paats,Joachim G J V Aerts,Adrianus J de Langen,Anne-Marie C Dingemans

Lung cancer (Amsterdam, Netherlands)（2023）

引用 0|浏览13

暂无评分

摘要

After progression on EGFR-TKI, patients with EGFR-mutated NSCLC show substantial benefit on different chemotherapy regimens. In particular, favorable outcomes were seen in patients treated with PP and CPBA as first-line chemotherapy, and PB in further lines of chemotherapy.

查看译文

关键词

nsclc,unselected treatment,efficacy,egfr-mutated,egfr-tki

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要